Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Leukemia

Free Subscription Articles published in Int J Hematol Retrieve available abstracts of 155 articles: HTML format

Single Articles

October 2023
1. FUKATSU M, Hamazaki Y, Sato Y, Koyama D, et al
   A case of cold agglutinin syndrome associated with chronic lymphocytic leukaemia harbouring mutations in CARD11 and KMT2D.
   Int J Hematol. 2023;118:472-476.
   PubMed     Abstract available
   
   
   September 2023
2. ZHANG A, Liu L, Zong S, Chang L, et al
   Pediatric acute myeloid leukemia and hyperleukocytosis with WBC count greater than 50 x 10(9)/L.
   Int J Hematol. 2023 Sep 21. doi: 10.1007/s12185-023-03665.
   PubMed     Abstract available
   
   
   
3. HARA R, Machida S, Hashimoto N, Ogiya D, et al
   Impact of previous anthracycline therapy in patients with acute myeloid leukemia receiving venetoclax.
   Int J Hematol. 2023 Sep 20. doi: 10.1007/s12185-023-03664.
   PubMed     Abstract available
   
   
   
4. YAMAMOTO M, Akane Y, Hamada R, Kabutoya H, et al
   Rivaroxaban for severe superior sagittal sinus thrombosis in a child with ALL.
   Int J Hematol. 2023;118:309-310.
   PubMed    
   
   
   August 2023
5. IZUTSU K, Yamamoto K, Kato K, Ishikawa T, et al
   Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.
   Int J Hematol. 2023 Aug 15. doi: 10.1007/s12185-023-03646.
   PubMed    
   
   
   
6. OKAMOTO K, Imamura T, Tanaka S, Urata T, et al
   The Nup98::Nsd1 fusion gene induces CD123 expression in 32D cells.
   Int J Hematol. 2023;118:277-287.
   PubMed     Abstract available
   
   
   
7. NAJIMA Y
   Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS.
   Int J Hematol. 2023;118:169-182.
   PubMed     Abstract available
   
   
   July 2023
8. BABA Y, Nakamaki T, Sakai H, Fukuchi K, et al
   Chronic neutrophilic leukemia preceded by myelodysplastic syndromes.
   Int J Hematol. 2023 Jul 13. doi: 10.1007/s12185-023-03636.
   PubMed     Abstract available
   
   
   June 2023
9. YANO M, Ishida H, Hara J, Kawaguchi H, et al
   Outcome of hematopoietic stem cell transplantation in pediatric patients with acute lymphoblastic leukemia not in remission enrolled in JACLS ALL-02.
   Int J Hematol. 2023 Jun 26. doi: 10.1007/s12185-023-03626.
   PubMed     Abstract available
   
   
   
10. HAEFLIGER S, Tzankov A
    Mycobacterial spindle cell pseudotumor mimicking Richter transformation in a patient with hairy cell leukemia.
    Int J Hematol. 2023 Jun 23. doi: 10.1007/s12185-023-03628.
    PubMed    
    
    
    
11. FUJITA T, Fukushima H, Nanmoku T, Arakawa Y, et al
    Acute monocytic leukemia with KMT2A::LASP1 developed 9 months after diagnosis of acute megakaryoblastic leukemia in a 2-year-old boy.
    Int J Hematol. 2023 Jun 14. doi: 10.1007/s12185-023-03622.
    PubMed     Abstract available
    
    
    
12. BARAKAT C, Inagaki Y, Mizuno S, Nishio N, et al
    Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation.
    Int J Hematol. 2023 Jun 13. doi: 10.1007/s12185-023-03621.
    PubMed     Abstract available
    
    
    
13. ZHAO Y, Jiang S, Tang Y, Zhao L, et al
    Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review.
    Int J Hematol. 2023 Jun 3. doi: 10.1007/s12185-023-03623.
    PubMed     Abstract available
    
    
    
14. SASHIDA G
    Stem cell regulation and dynamics in myeloid malignancies.
    Int J Hematol. 2023;117:789-790.
    PubMed     Abstract available
    
    
    
15. ABDALLAH MG, Teoh VSI, Dutta B, Yokomizo T, et al
    Childhood hematopoietic stem cells constitute the permissive window for RUNX1-ETO leukemogenesis.
    Int J Hematol. 2023;117:830-838.
    PubMed     Abstract available
    
    
    
16. YANG FC, Agosto-Pena J
    Epigenetic regulation by ASXL1 in myeloid malignancies.
    Int J Hematol. 2023;117:791-806.
    PubMed     Abstract available
    
    
    
17. JIN Z, MacPherson K, Liu Z, Vu LP, et al
    RNA modifications in hematological malignancies.
    Int J Hematol. 2023;117:807-820.
    PubMed     Abstract available
    
    
    
18. TUNGALAG S, Shinriki S, Hirayama M, Nagamachi A, et al
    Ribosome profiling analysis reveals the roles of DDX41 in translational regulation.
    Int J Hematol. 2023;117:876-888.
    PubMed     Abstract available
    
    
    
19. FUKUTA T, Tanaka T, Hashimoto T, Isahaya K, et al
    Nelarabine-induced myelopathy in patients undergoing allogeneic hematopoietic cell transplantation: a report of three cases.
    Int J Hematol. 2023;117:933-940.
    PubMed     Abstract available
    
    
    May 2023
20. ZHANG X, Cui B, Li Y, Li Z, et al
    Transcriptome sequencing identifies novel EVX fusions involved in transcriptional activation of HOX family genes in pediatric immature T-cell acute lymphoblastic leukemia: two cases reports and a literature review.
    Int J Hematol. 2023 May 27. doi: 10.1007/s12185-023-03619.
    PubMed     Abstract available
    
    
    
21. AL-SHAIBANI E, Novitzky-Basso I, Mattsson J, Kim DDH, et al
    Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy.
    Int J Hematol. 2023 May 22. doi: 10.1007/s12185-023-03614.
    PubMed     Abstract available
    
    
    
22. TOKUHIRA M, Kimura Y, Tabayashi T, Watanabe N, et al
    Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects.
    Int J Hematol. 2023 May 2. doi: 10.1007/s12185-023-03606.
    PubMed     Abstract available
    
    
    
23. MIYAGAWA N, Goto H, Ogawa A, Kikuta A, et al
    Phase 2 study of combination chemotherapy with bortezomib in children with relapsed and refractory acute lymphoblastic leukemia.
    Int J Hematol. 2023 May 1. doi: 10.1007/s12185-023-03609.
    PubMed     Abstract available
    
    
    April 2023
24. LANGABEER SE, Jones A, Conneally E, Enright H, et al
    Frequency and driver mutation diversity of concomitant chronic myeloid leukemia and Philadelphia chromosome-negative myeloproliferative neoplasm.
    Int J Hematol. 2023 Apr 26. doi: 10.1007/s12185-023-03611.
    PubMed    
    
    
    
25. IMAI C, Sato A, Hiwatari M, Shimomura Y, et al
    Outcomes following induction failure in Japanese children with acute lymphoblastic leukemia.
    Int J Hematol. 2023 Apr 10. doi: 10.1007/s12185-023-03600.
    PubMed     Abstract available
    
    
    
26. NOGUCHI K, Ikawa Y, Takenaka M, Sakai Y, et al
    L-asparaginase as an efficient salvage therapy for refractory acute myeloid leukemia with chromosome 7 abnormalities: a case series.
    Int J Hematol. 2023 Apr 6. doi: 10.1007/s12185-023-03591.
    PubMed     Abstract available
    
    
    
27. MUNAKATA W, Ando K, Yokoyama M, Fukuhara N, et al
    Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies.
    Int J Hematol. 2023;117:553-562.
    PubMed     Abstract available
    
    
    March 2023
28. FUKUSHIMA H, Morita K, Ikemura M, Tanaka M, et al
    Acute pancreatitis as the initial manifestation of acute myeloid leukemia with chromosome 16 rearrangements.
    Int J Hematol. 2023 Mar 25. doi: 10.1007/s12185-023-03580.
    PubMed     Abstract available
    
    
    
29. NAKAYAMA H, Ogawa C, Sekimizu M, Fujisaki H, et al
    Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).
    Int J Hematol. 2023 Mar 21. doi: 10.1007/s12185-023-03584.
    PubMed    
    
    
    
30. NAKAMURA F, Seo S, Nannya Y, Ayabe R, et al
    Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12).
    Int J Hematol. 2023 Mar 17. doi: 10.1007/s12185-023-03577.
    PubMed     Abstract available
    
    
    
31. TORATANI K, Watanabe M, Kanda J, Oka T, et al
    Unrelated hematopoietic stem cell transplantation for familial platelet disorder/acute myeloid leukemia with germline RUNX1 mutations.
    Int J Hematol. 2023 Mar 10. doi: 10.1007/s12185-023-03575.
    PubMed     Abstract available
    
    
    
32. ALEEM A, Alotaibi G, Iqbal Z, AlFaifi A, et al
    Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia.
    Int J Hematol. 2023 Mar 9. doi: 10.1007/s12185-023-03569.
    PubMed     Abstract available
    
    
    
33. SHIRAI R, Osumi T, Keino D, Nakabayashi K, et al
    Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.
    Int J Hematol. 2023 Mar 3. doi: 10.1007/s12185-023-03566.
    PubMed     Abstract available
    
    
    
34. ZHENG Q, Liao H
    Blasts engulfing erythrocytes: an unusual morphological finding in adult early T-precursor acute lymphoblastic leukemia.
    Int J Hematol. 2023 Mar 2. doi: 10.1007/s12185-023-03574.
    PubMed    
    
    
    
35. KATSUYA H
    Current and emerging therapeutic strategies in adult T-cell leukemia-lymphoma.
    Int J Hematol. 2023 Mar 2. doi: 10.1007/s12185-023-03572.
    PubMed     Abstract available
    
    
    
36. OLIVEIRA AC, Roncero JM, Ferra C, Do Nascimento J, et al
    Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies.
    Int J Hematol. 2023;117:388-397.
    PubMed     Abstract available
    
    
    
37. HAJI S, Shiratsuchi M, Takamatsu A, Tsuda M, et al
    Endothelial function testing before conditioning therapy is useful for predicting transplant-related complications after allogeneic hematopoietic cell transplantation.
    Int J Hematol. 2023;117:438-445.
    PubMed     Abstract available
    
    
    February 2023
38. MIYASHITA N, Onozawa M, Yoshida S, Kimura H, et al
    Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.
    Int J Hematol. 2023 Feb 28. doi: 10.1007/s12185-023-03567.
    PubMed     Abstract available
    
    
    
39. WAKAMATSU M, Murata M, Kanda J, Fukushima K, et al
    Different effects of thymoglobulin on acute leukemia with pre-transplant residual blasts in HLA mismatch transplantation.
    Int J Hematol. 2023 Feb 22. doi: 10.1007/s12185-023-03563.
    PubMed     Abstract available
    
    
    
40. NAKASONE H
    Prophylactic or preemptive tyrosine kinase inhibitor therapy after allogeneic hematopoietic cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Int J Hematol. 2023 Feb 20. doi: 10.1007/s12185-023-03556.
    PubMed     Abstract available
    
    
    
41. ONISHI Y, Furukawa E, Kamata M, Fukatsu M, et al
    Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL.
    Int J Hematol. 2023 Feb 9. doi: 10.1007/s12185-023-03546.
    PubMed     Abstract available
    
    
    
42. YOSHIDA C, Yamaguchi H, Doki N, Murai K, et al
    Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study.
    Int J Hematol. 2023 Feb 4. doi: 10.1007/s12185-023-03549.
    PubMed     Abstract available
    
    
    
43. OBO T, Morita K, Sumida Y, Nakazaki-Watadani K, et al
    Isolated relapse of plasma cell leukemia in the central nervous systems: a case report and literature review.
    Int J Hematol. 2023 Feb 3. doi: 10.1007/s12185-023-03545.
    PubMed     Abstract available
    
    
    
44. ZHANG M, Xiao F, Li Y, Chen Z, et al
    The miR-106b-25 cluster mediates drug resistance in myeloid leukaemias by inactivating multiple apoptotic genes.
    Int J Hematol. 2023;117:236-250.
    PubMed     Abstract available
    
    
    
45. IMAIZUMI Y, Iwanaga M, Nosaka K, Ishitsuka K, et al
    Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study.
    Int J Hematol. 2023;117:206-215.
    PubMed     Abstract available
    
    
    
46. TANIGUCHI S, Utsumi S, Kochi Y, Taya Y, et al
    Successful pseudo-autologous stem cell transplantation for donor-derived Burkitt lymphoma occurring 9 years after allogeneic transplantation.
    Int J Hematol. 2023;117:287-292.
    PubMed     Abstract available
    
    
    January 2023
47. YASUNAGA JI
    Viral, genetic, and immune factors in the oncogenesis of adult T-cell leukemia/lymphoma.
    Int J Hematol. 2023 Jan 27. doi: 10.1007/s12185-023-03547.
    PubMed     Abstract available
    
    
    
48. LIU H, Bai H, Zhang S, Zhao X, et al
    Dasatinib for chronic myelomonocytic leukemia with ZMIZ1-ABL1 fusion gene: a case report.
    Int J Hematol. 2023 Jan 24. doi: 10.1007/s12185-023-03531.
    PubMed     Abstract available
    
    
    
49. SHIBA N
    Comprehensive molecular understanding of pediatric acute myeloid leukemia.
    Int J Hematol. 2023 Jan 18. doi: 10.1007/s12185-023-03533.
    PubMed     Abstract available
    
    
    
50. IMAMURA T
    Guest editorial: recent progress in pediatric leukemia.
    Int J Hematol. 2023 Jan 13. doi: 10.1007/s12185-023-03536.
    PubMed     Abstract available
    
    
    
51. CAI Y, Zhang J, Yi M, Zhang W, et al
    Short-term efficacy of decitabine-based therapy in JMML: a retrospective study from a single center in China.
    Int J Hematol. 2023;117:121-127.
    PubMed     Abstract available
    
    
    December 2022
52. ZHANG X, Wu S, Yang J, Zhang G, et al
    Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia.
    Int J Hematol. 2022 Dec 29. doi: 10.1007/s12185-022-03507.
    PubMed     Abstract available
    
    
    
53. HIROKI H, Akahane K, Inukai T, Morio T, et al
    Synergistic effect of combined PI3 kinase inhibitor and PARP inhibitor treatment on BCR/ABL1-positive acute lymphoblastic leukemia cells.
    Int J Hematol. 2022 Dec 28. doi: 10.1007/s12185-022-03520.
    PubMed     Abstract available
    
    
    
54. SHIMA H, Shimada H
    Recent progress in the management of pediatric chronic myeloid leukemia.
    Int J Hematol. 2022 Dec 27. doi: 10.1007/s12185-022-03526.
    PubMed     Abstract available
    
    
    
55. YOSHIDA S, Onozawa M, Miyashita N, Kimura H, et al
    Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia.
    Int J Hematol. 2022 Dec 26. doi: 10.1007/s12185-022-03522.
    PubMed     Abstract available
    
    
    
56. LI H, Niu T, Huang J, Xie L, et al
    The characteristics and long-term outcomes of acute promyelocytic leukemia patients with early intracranial hemorrhage.
    Int J Hematol. 2022 Dec 15. doi: 10.1007/s12185-022-03515.
    PubMed     Abstract available
    
    
    
57. IRIYAMA N
    Chronic myeloid leukemia: the cutting-edge evidence and things we should know.
    Int J Hematol. 2022 Dec 8. doi: 10.1007/s12185-022-03511.
    PubMed     Abstract available
    
    
    
58. OCHI Y
    Genetic landscape of chronic myeloid leukemia.
    Int J Hematol. 2022 Dec 7. doi: 10.1007/s12185-022-03510.
    PubMed     Abstract available
    
    
    
59. GAO L, Lu J, Li J, Hu Y, et al
    Lineage switch in a pediatric patient with KMT2A-MLLT3 from acute megakaryoblastic leukemia to T cell acute lymphoblastic leukemia at the fourth relapse after allo-HSCT: with literature review.
    Int J Hematol. 2022 Dec 6. doi: 10.1007/s12185-022-03504.
    PubMed     Abstract available
    
    
    
60. IWAI T, Nishida M, Sugita J, Yasumoto A, et al
    Ultrasonographic monitoring of sinusoidal obstruction syndrome in patients treated with inotuzumab ozogamicin.
    Int J Hematol. 2022;116:973-975.
    PubMed    
    
    
    
61. KATO M
    Recent progress in pediatric lymphoblastic leukemia.
    Int J Hematol. 2022 Dec 1. doi: 10.1007/s12185-022-03501.
    PubMed     Abstract available
    
    
    November 2022
62. TOMIZAWA D
    Evolution and optimization of therapies for acute lymphoblastic leukemia in infants.
    Int J Hematol. 2022 Nov 28. doi: 10.1007/s12185-022-03502.
    PubMed     Abstract available
    
    
    
63. KARADAS N, Goktepe SSO, Bas I, Ece D, et al
    Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment.
    Int J Hematol. 2022 Nov 19. doi: 10.1007/s12185-022-03497.
    PubMed     Abstract available
    
    
    
64. NAKAMURA Y, Itoh Y, Wakimoto N
    Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia.
    Int J Hematol. 2022 Nov 14. pii: 10.1007/s12185-022-03492.
    PubMed     Abstract available
    
    
    
65. YANADA M, Yamasaki S, Konuma T, Mizuno S, et al
    Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia.
    Int J Hematol. 2022 Nov 6. pii: 10.1007/s12185-022-03486.
    PubMed     Abstract available
    
    
    
66. WAN L, Ding S, Xu M, Lv K, et al
    Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML.
    Int J Hematol. 2022;116:731-743.
    PubMed     Abstract available
    
    
    
67. LI W, Xu Y, Feng Y, Zhou H, et al
    The clinical application of SNP-based next-generation sequencing (SNP-NGS) for evaluation of chimerism and microchimerism after HLA-mismatched stem cell microtransplantation.
    Int J Hematol. 2022;116:723-730.
    PubMed     Abstract available
    
    
    
68. LEE FW, Lee CY, Hung GY, Tseng MH, et al
    Recurrent microangiopathic hemolysis after recovery from complement-mediated hemolytic uremia syndrome during chemotherapy for a CFH-mutated patient with T-lymphoblastic lymphoma.
    Int J Hematol. 2022;116:812-818.
    PubMed     Abstract available
    
    
    
69. KUSUDA M, Nakasone H, Nakamura Y, Kawamura M, et al
    Very early death within 30 days after diagnosis in patients with acute myeloid leukemia.
    Int J Hematol. 2022 Nov 1. pii: 10.1007/s12185-022-03482.
    PubMed     Abstract available
    
    
    October 2022
70. VINOTHKUMAR K, Chanda S, Singh VK, Biswas S, et al
    EVI1 upregulates PTGS1 (COX1) and decreases the action of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia cells.
    Int J Hematol. 2022 Oct 25. pii: 10.1007/s12185-022-03465.
    PubMed     Abstract available
    
    
    
71. ITO J, Yamagata K, Shinohara H, Shima Y, et al
    Dual inhibition of EZH1/2 induces cell cycle arrest of B cell acute lymphoblastic leukemia cells through upregulation of CDKN1C and TP53INP1.
    Int J Hematol. 2022 Oct 24. pii: 10.1007/s12185-022-03469.
    PubMed     Abstract available
    
    
    
72. YUNIS LK, Linares-Ballesteros A, Barros G, Garcia J, et al
    Genomic alterations in a cohort of pediatric acute myeloid leukemia patients at two cancer centers in Colombia.
    Int J Hematol. 2022 Oct 24. pii: 10.1007/s12185-022-03475.
    PubMed     Abstract available
    
    
    
73. SEKIGUCHI N, Kasahara S, Miyamoto T, Kiguchi T, et al
    Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia.
    Int J Hematol. 2022 Oct 19. pii: 10.1007/s12185-022-03464.
    PubMed     Abstract available
    
    
    
74. LEIVA O, Ren S, Neuberg D, Bhatt A, et al
    Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease.
    Int J Hematol. 2022 Oct 2. pii: 10.1007/s12185-022-03454.
    PubMed     Abstract available
    
    
    
75. HOCHMAN MJ, Smith BD, Karantanos T, Braunstein EM, et al
    Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency.
    Int J Hematol. 2022 Oct 1. pii: 10.1007/s12185-022-03463.
    PubMed     Abstract available
    
    
    September 2022
76. UMEZAWA Y, Sasaki K
    Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
    Int J Hematol. 2022 Sep 10. pii: 10.1007/s12185-022-03431.
    PubMed     Abstract available
    
    
    
77. SUN H, Yan Z, Zhang S
    Three atypical BCR/ABL transcripts detected simultaneously in a Philadelphia-positive acute lymphoblastic leukemia patient showing resistance to tyrosine kinase inhibitors.
    Int J Hematol. 2022 Sep 10. pii: 10.1007/s12185-022-03451.
    PubMed     Abstract available
    
    
    
78. HIROSAWA M, Goto M, Oku M, Akao K, et al
    Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study.
    Int J Hematol. 2022 Sep 9. pii: 10.1007/s12185-022-03447.
    PubMed     Abstract available
    
    
    
79. NARLI OZDEMIR Z, Kilicaslan NA, Yilmaz M, Eskazan AE, et al
    Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities.
    Int J Hematol. 2022 Sep 5. pii: 10.1007/s12185-022-03446.
    PubMed     Abstract available
    
    
    
80. MAGNOLI F, Casiccia L, Ripamonti F, Uccella S, et al
    Simultaneous diagnosis of plasma cell myeloma and chronic lymphocytic leukemia on bone marrow trephine biopsy.
    Int J Hematol. 2022 Sep 2. pii: 10.1007/s12185-022-03443.
    PubMed    
    
    
    
81. BIAVASCO F, Zeiser R
    FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation.
    Int J Hematol. 2022;116:341-350.
    PubMed     Abstract available
    
    
    August 2022
82. HAN L, Li Y, Wu J, Peng J, et al
    Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1.
    Int J Hematol. 2022 Aug 28. pii: 10.1007/s12185-022-03441.
    PubMed     Abstract available
    
    
    
83. HOSHINO T, Hatsumi N, Iino H, Takada S, et al
    Therapy-related myeloid neoplasms of recipient origin after allogeneic hematopoietic stem cell transplantation for acute leukemia.
    Int J Hematol. 2022 Aug 28. pii: 10.1007/s12185-022-03442.
    PubMed     Abstract available
    
    
    
84. SUZUMIYA J, Takizawa J
    Correction to: Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
    Int J Hematol. 2022 Aug 27. pii: 10.1007/s12185-022-03439.
    PubMed    
    
    
    
85. ONO T, Hino M, Matsumura I, Fujisawa S, et al
    Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study.
    Int J Hematol. 2022 Aug 13. pii: 10.1007/s12185-022-03435.
    PubMed     Abstract available
    
    
    
86. AYDIN S, Passera R, Scaldaferri M, Dellacasa CM, et al
    Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia.
    Int J Hematol. 2022 Aug 9. pii: 10.1007/s12185-022-03427.
    PubMed     Abstract available
    
    
    
87. TSUDA M, Hirata A, Tokunaga S, Masuda T, et al
    Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin-aldosterone-angiotensin system inhibitors in patients with chronic myelogenous leukemia.
    Int J Hematol. 2022 Aug 6. pii: 10.1007/s12185-022-03433.
    PubMed     Abstract available
    
    
    
88. LAGANA A, Scalzulli E, Carmosino I, Martelli M, et al
    Asciminib as a third line option in chronic myeloid leukemia.
    Int J Hematol. 2022 Aug 5. pii: 10.1007/s12185-022-03432.
    PubMed     Abstract available
    
    
    July 2022
89. HIRADE K, Kusumoto S, Abe A, Noritake H, et al
    A novel RARA-SNX15 fusion in PML-RARA-positive acute promyelocytic leukemia with t(11;17;15)(q13;q21.2;q24.1).
    Int J Hematol. 2022 Jul 19. pii: 10.1007/s12185-022-03421.
    PubMed     Abstract available
    
    
    
90. HAGINO T, Sato T, Saga R, Hidai H, et al
    Myeloid leukemoid reaction after initial azacitidine therapy for chronic myelomonocytic leukemia.
    Int J Hematol. 2022 Jul 19. pii: 10.1007/s12185-022-03422.
    PubMed     Abstract available
    
    
    
91. CHEN X, Liu L, Zhang A, Yi M, et al
    Droplet digital PCR for genetic mutations monitoring predicts relapse risk in pediatric acute myeloid leukemia.
    Int J Hematol. 2022 Jul 18. pii: 10.1007/s12185-022-03402.
    PubMed     Abstract available
    
    
    
92. KREIDIEH F, Abou Dalle I, Moukalled N, El-Cheikh J, et al
    Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment.
    Int J Hematol. 2022 Jul 16. pii: 10.1007/s12185-022-03416.
    PubMed     Abstract available
    
    
    
93. MIYAJIMA T, Hasegawa Y, Hashimoto D, Teshima T, et al
    Unilateral recurrent laryngeal nerve palsy detected by PET/CT in a patient with mediastinal T-cell lymphoblastic lymphoma.
    Int J Hematol. 2022;116:3-4.
    PubMed    
    
    
    
94. YOSHIDA C, Kondo T, Ito T, Kizaki M, et al
    Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy.
    Int J Hematol. 2022;116:89-101.
    PubMed     Abstract available
    
    
    
95. HE J, Liu J, Shen H, Wang Z, et al
    Companion gene mutations and their clinical significance in AML with double or single mutant CEBPA.
    Int J Hematol. 2022;116:71-80.
    PubMed     Abstract available
    
    
    June 2022
96. CAO XY, Li JJ, Lu PH, Liu KY, et al
    Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2022 Jun 23. pii: 10.1007/s12185-022-03398.
    PubMed     Abstract available
    
    
    
97. MATSUOKA A, Tanibuchi M, Yamazaki I, Taoka T, et al
    Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine.
    Int J Hematol. 2022;115:852-859.
    PubMed     Abstract available
    
    
    
98. KAWAKAMI F, Kawakami T, Yamane T, Maruyama M, et al
    T cell clonal expansion and STAT3 mutations: a characteristic feature of acquired chronic T cell-mediated pure red cell aplasia.
    Int J Hematol. 2022;115:816-825.
    PubMed     Abstract available
    
    
    
99. ONISHI Y, Onodera K, Fukuhara N, Kato H, et al
    Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders.
    Int J Hematol. 2022;115:873-881.
    PubMed     Abstract available
    
    
    
100. WATANABE N, Takaku T, Tsukune Y, Yasuda H, et al
     Bosutinib-induced lung injury: a report of two cases and literature review.
     Int J Hematol. 2022;115:902-905.
     PubMed     Abstract available
     
     
     May 2022
101. NAKAYAMA H, Ogawa C, Sekimizu M, Fujisaki H, et al
     A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).
     Int J Hematol. 2022 May 30. pii: 10.1007/s12185-022-03388.
     PubMed     Abstract available
     
     
     
102. CAPRIA S, Trisolini SM, Diverio D, Minotti C, et al
     Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges.
     Int J Hematol. 2022 May 13. pii: 10.1007/s12185-022-03370.
     PubMed     Abstract available
     
     
     
103. MIZUTA S, Ugai T, Kato H, Doki N, et al
     Propensity score matching/reweighting analysis comparing autologous and allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
     Int J Hematol. 2022 May 10. pii: 10.1007/s12185-022-03368.
     PubMed     Abstract available
     
     
     
104. TACHIBANA T, Tanaka M, Hagihara M, Fujimaki K, et al
     Outcomes in patients with acute lymphoblastic leukemia who underwent second allogeneic hematopoietic cell transplantation for relapse after first transplantation.
     Int J Hematol. 2022 May 9. pii: 10.1007/s12185-022-03377.
     PubMed     Abstract available
     
     
     
105. ARAI Y, Chi S, Minami Y, Yanada M, et al
     FLT3-targeted treatment for acute myeloid leukemia.
     Int J Hematol. 2022 May 9. pii: 10.1007/s12185-022-03374.
     PubMed     Abstract available
     
     
     
106. NGUYEN TTT, Tamai M, Harama D, Kagami K, et al
     Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system.
     Int J Hematol. 2022 May 6. pii: 10.1007/s12185-022-03369.
     PubMed     Abstract available
     
     
     
107. FUKUYAMA T, Kitamura T, Kozu T
     UBC9 inhibits myeloid differentiation in collaboration with AML1-MTG8.
     Int J Hematol. 2022;115:686-693.
     PubMed     Abstract available
     
     
     
108. LU N, Lin J, Wang LL, Li YY, et al
     A retrospective single-center analysis of G-CSF-mobilized donor lymphocyte infusion in hematologic malignancies after unmanipulated allogenic PBSCT.
     Int J Hematol. 2022;115:713-727.
     PubMed     Abstract available
     
     
     April 2022
109. SOBIERALSKI P, Bieniaszewska M, Leszczynska A, Zuk M, et al
     Secondary chronic myeloid leukemia in a patient with CALR and ASXL1-mutated primary myelofibrosis.
     Int J Hematol. 2022 Apr 16. pii: 10.1007/s12185-022-03331.
     PubMed     Abstract available
     
     
     
110. HAYAKAWA J, Nakasone H, Minakata D, Fujiwara SI, et al
     Comparison of the impact of two post-remission therapy regimens on cardiac events in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
     Int J Hematol. 2022 Apr 16. pii: 10.1007/s12185-022-03343.
     PubMed     Abstract available
     
     
     
111. MARUMO A, Wakita S, Morita K, Oh I, et al
     NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.
     Int J Hematol. 2022 Apr 4. pii: 10.1007/s12185-022-03328.
     PubMed     Abstract available
     
     
     March 2022
112. KODAMA Y, Sato A, Kato K, Sakaguchi H, et al
     Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children's Cancer Group.
     Int J Hematol. 2022 Mar 29. pii: 10.1007/s12185-022-03329.
     PubMed     Abstract available
     
     
     
113. TASHIRO Y, Kanda J, Iemura T, Kondo T, et al
     Feasibility of ovarian stimulation for fertility preservation during and after blinatumomab treatment for Ph-negative B-cell acute lymphoblastic leukemia.
     Int J Hematol. 2022 Mar 14. pii: 10.1007/s12185-022-03323.
     PubMed     Abstract available
     
     
     
114. TAKAHASHI Y, Ishida H, Imamura T, Tamefusa K, et al
     JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia.
     Int J Hematol. 2022 Mar 8. pii: 10.1007/s12185-022-03315.
     PubMed     Abstract available
     
     
     
115. TAKAHASHI N, Cortes JE, Sakaida E, Ishizawa K, et al
     Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.
     Int J Hematol. 2022 Mar 2. pii: 10.1007/s12185-022-03314.
     PubMed     Abstract available
     
     
     
116. ADACHI Y, Sakai T, Terakura S, Shiina T, et al
     Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells.
     Int J Hematol. 2022;115:371-381.
     PubMed     Abstract available
     
     
     February 2022
117. KOJIMA H, Nakayama H, Kosugi N
     Bilateral adrenal hemorrhage: a rare presentation of acute myeloid leukemia.
     Int J Hematol. 2022 Feb 25. pii: 10.1007/s12185-022-03316.
     PubMed    
     
     
     
118. HWANG WL, Chen TC, Lin HY, Chang MC, et al
     NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan.
     Int J Hematol. 2022 Feb 25. pii: 10.1007/s12185-022-03311.
     PubMed     Abstract available
     
     
     
119. IIDA H, Imada K, Ueda Y, Kubo K, et al
     A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia.
     Int J Hematol. 2022 Feb 24. pii: 10.1007/s12185-022-03307.
     PubMed     Abstract available
     
     
     
120. CHENG S, Xiao P, Wang J, Li Z, et al
     Decitabine combined with minimally myelosuppressive therapy for induction of remission in pediatric high-risk acute myeloid leukemia with chromosome 5q deletion: a report of three cases.
     Int J Hematol. 2022 Feb 18. pii: 10.1007/s12185-022-03309.
     PubMed     Abstract available
     
     
     
121. SATO S, Tamai Y
     Acute monocytic leukemia with histiocytic morphology in hematological remission after azacytidine and venetoclax therapy.
     Int J Hematol. 2022 Feb 8. pii: 10.1007/s12185-022-03296.
     PubMed    
     
     
     
122. MORI A, Onozawa M, Hidaka D, Yokoyama S, et al
     Non-age-related neoplastic loss of sex chromosome correlated with prolonged survival in real-world CBF-AML patients.
     Int J Hematol. 2022;115:188-197.
     PubMed     Abstract available
     
     
     
123. SAWADA A, Shimizu M, Koyama-Sato M, Higuchi K, et al
     Radiation-sparing reduced-intensity unrelated umbilical cord blood transplantation for rare hematological disorders in children.
     Int J Hematol. 2022;115:269-277.
     PubMed     Abstract available
     
     
     
124. WEI X, Zhuang J, Li N, Zheng B, et al
     NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China.
     Int J Hematol. 2022;115:278-286.
     PubMed     Abstract available
     
     
     January 2022
125. HIGUCHI K, Sawada A, Kondo O, Okada Y, et al
     HLA-haploidentical peripheral blood stem cell transplantation following reduced-intensity conditioning with very low-dose antithymocyte globulin for relapsed/refractory acute leukemia in pediatric patients: a single-institution retrospective analysis.
     Int J Hematol. 2022 Jan 14. pii: 10.1007/s12185-021-03270.
     PubMed     Abstract available
     
     
     
126. AKAHOSHI Y, Nakasone H, Kusuda M, Kameda K, et al
     Emergence of clone with PHF6 nonsense mutation in chronic myelomonocytic leukemia at relapse after allogeneic HCT.
     Int J Hematol. 2022 Jan 6. pii: 10.1007/s12185-021-03284.
     PubMed     Abstract available
     
     
     
127. BABA M, Imamura M, Imai C
     Newly diagnosed ETV6-RUNX1-positive B-acute lymphoblastic leukemia localized to the left pelvic bone marrow.
     Int J Hematol. 2022 Jan 4. pii: 10.1007/s12185-021-03269.
     PubMed    
     
     
     
128. GOMEZ-CENTURION I, Oarbeascoa G, Garcia MC, Lopez Fresnena MC, et al
     Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility.
     Int J Hematol. 2022;115:61-68.
     PubMed     Abstract available
     
     
     December 2021
129. OHWADA C, Yamazaki S, Shono K, Kayamori K, et al
     Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation.
     Int J Hematol. 2021;114:664-673.
     PubMed     Abstract available
     
     
     November 2021
130. KOBAYASHI S, Sano H, Mochizuki K, Ohara Y, et al
     Effects of second transplantation with T-cell-replete haploidentical graft using low-dose anti-thymocyte globulin on long-term overall survival in pediatric patients with relapse of leukemia after first allogeneic transplantation.
     Int J Hematol. 2021 Nov 25. pii: 10.1007/s12185-021-03266.
     PubMed     Abstract available
     
     
     
131. NAKAMAE M, Nakamae H, Hashimoto M, Koh H, et al
     Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors.
     Int J Hematol. 2021 Nov 17. pii: 10.1007/s12185-021-03259.
     PubMed     Abstract available
     
     
     
132. WANG X, Diamond DJ, Forman SJ, Nakamura R, et al
     Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine.
     Int J Hematol. 2021;114:544-553.
     PubMed     Abstract available
     
     
     October 2021
133. HONDA Y, Muramatsu H, Nanjo Y, Hirabayashi S, et al
     A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia.
     Int J Hematol. 2021 Oct 29. pii: 10.1007/s12185-021-03248.
     PubMed     Abstract available
     
     
     
134. INOUE Y, Nishimura N, Murai M, Matsumoto M, et al
     Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation.
     Int J Hematol. 2021 Oct 27. pii: 10.1007/s12185-021-03250.
     PubMed     Abstract available
     
     
     
135. SHIBATA S, Inano S, Watanabe M, Fujiwara K, et al
     Identification of an asymptomatic Shwachman-Bodian-Diamond syndrome mutation in a patient with acute myeloid leukemia.
     Int J Hematol. 2021 Oct 26. pii: 10.1007/s12185-021-03251.
     PubMed     Abstract available
     
     
     
136. IKAWA Y, Takenaka M, Sakai Y, Noguchi K, et al
     Utility of 18F-FDG-PET for detecting acute lymphoblastic leukemia: a case series of pediatric acute lymphoblastic leukemia without hematological symptoms.
     Int J Hematol. 2021 Oct 13. pii: 10.1007/s12185-021-03232.
     PubMed     Abstract available
     
     
     
137. NUKUI J, Tanaka M, Nakajima H
     A case of multiple brain abscesses due to Bacillus cereus during induction therapy for acute myeloid leukemia.
     Int J Hematol. 2021 Oct 7. pii: 10.1007/s12185-021-03226.
     PubMed    
     
     
     
138. LEE SH, Yoon JH, Min GJ, Park SS, et al
     Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.
     Int J Hematol. 2021 Oct 6. pii: 10.1007/s12185-021-03231.
     PubMed     Abstract available
     
     
     
139. KAWANO N, Kimura S, Miura M, Tochigi T, et al
     Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL.
     Int J Hematol. 2021;114:509-516.
     PubMed     Abstract available
     
     
     September 2021
140. DEMBITZ V, Lalic H, Tomic B, Smoljo T, et al
     All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16.
     Int J Hematol. 2021 Sep 21. pii: 10.1007/s12185-021-03224.
     PubMed     Abstract available
     
     
     
141. NAKAMAE H, Yamamoto M, Sakaida E, Kanda Y, et al
     Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year followup of the Japanese subgroup of the randomized ENESTnd trial.
     Int J Hematol. 2021 Sep 11. pii: 10.1007/s12185-021-03216.
     PubMed     Abstract available
     
     
     
142. IZUMI A, Tachibana T, Ando T, Tanaka M, et al
     A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation.
     Int J Hematol. 2021 Sep 6. pii: 10.1007/s12185-021-03217.
     PubMed     Abstract available
     
     
     August 2021
143. HAN W, Zhou F, Wang Z, Hua H, et al
     Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.
     Int J Hematol. 2021 Aug 27. pii: 10.1007/s12185-021-03210.
     PubMed     Abstract available
     
     
     July 2021
144. KAKO S, Hayakawa F, Imai K, Tanaka J, et al
     Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy.
     Int J Hematol. 2021 Jul 30. pii: 10.1007/s12185-021-03198.
     PubMed     Abstract available
     
     
     
145. SATOH T, Kayano H, Watanabe A, Ohta A, et al
     Lethal macrophage-related complications of juvenile myelomonocytic leukemia with a blastic crisis: an autopsy case report.
     Int J Hematol. 2021 Jul 16. pii: 10.1007/s12185-021-03189.
     PubMed     Abstract available
     
     
     June 2021
146. LV K, Cai C, Chen J, Xu M, et al
     Prognostic value of lymphoid marker CD7 expression in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in first morphological complete remission.
     Int J Hematol. 2021 Jun 26. pii: 10.1007/s12185-021-03182.
     PubMed     Abstract available
     
     
     
147. MORI T, Kikuchi T, Yamazaki R, Koda Y, et al
     Phase 1 study of plerixafor in combination with total body irradiation-based myeloablative conditioning for allogeneic hematopoietic stem cell transplantation.
     Int J Hematol. 2021;113:877-883.
     PubMed     Abstract available
     
     
     May 2021
148. ARAKAWA Y, Masutani S, Oshima K, Mitani Y, et al
     Asian population may have a lower incidence of hip osteonecrosis in childhood acute lymphoblastic leukemia.
     Int J Hematol. 2021 May 18. pii: 10.1007/s12185-021-03163.
     PubMed     Abstract available
     
     
     
149. MORITA K, Sasaki K
     Current status and novel strategy of CML.
     Int J Hematol. 2021;113:624-631.
     PubMed     Abstract available
     
     
     
150. KIMURA S
     Evolution of CML treatment.
     Int J Hematol. 2021;113:622-623.
     PubMed    
     
     
     
151. SHAN M, Lu Y, Yang M, Wang P, et al
     Characteristics and transplant outcome of myeloid sarcoma: a single-institute study.
     Int J Hematol. 2021;113:682-692.
     PubMed     Abstract available
     
     
     April 2021
152. KIDOGUCHI K, Ureshino H, Kizuka-Sano H, Yamaguchi K, et al
     Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
     Int J Hematol. 2021 Apr 27. pii: 10.1007/s12185-021-03156.
     PubMed     Abstract available
     
     
     
153. CHUAH C, Koh LP, Numbenjapon T, Zang DY, et al
     Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
     Int J Hematol. 2021 Apr 13. pii: 10.1007/s12185-021-03144.
     PubMed     Abstract available
     
     
     
154. KOBAYASHI T, Ubukawa K, Fujishima M, Takahashi N, et al
     Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis.
     Int J Hematol. 2021;113:600-605.
     PubMed     Abstract available
     
     
     February 2021
155. ONO R, Ashiarai M, Hirabayashi S, Mizuki K, et al
     Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
     Int J Hematol. 2021;113:297-301.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: